
MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2
Chemical Structure : MI353(A-582941)
CAS No.: 848591-90-2
Description
Chemical Structure : MI353(A-582941)
CAS No.: 848591-90-2

MI353(MI-353, MI 353, A-582941)
Catalog No.: URK-V2484 Only Used For Lab.
MI353 (CAS No.: 848591-90-2) is a potent and selective inhibitor of glycogen synthase kinase-3 (GSK-3), an important therapeutic target for a wide range of diseases including Alzheimer's disease, diabetes, and cancer.
Biological Activity
MI353 (CAS No.: 848591-90-2) is a potent and selective inhibitor of glycogen synthase kinase-3 (GSK-3), an important therapeutic target for a wide range of diseases including Alzheimer's disease, diabetes, and cancer.
GSK-3 is a serine/threonine kinase that regulates a variety of cellular processes, including glucose metabolism, cell proliferation, and apoptosis. Dysregulation of GSK-3 signaling has been implicated in the pathogenesis of many diseases, making it an attractive target for drug development.
MI353 selectively inhibits GSK-3α and GSK-3β with high potency (IC50 values of 12 nM and 9 nM, respectively) and good selectivity over other kinases. It has been shown to have beneficial effects in various preclinical models of disease, including neuroprotection in Alzheimer's disease models and anti-tumor activity in multiple cancer types.
The mechanism of action of MI353 involves binding to the ATP-binding pocket of GSK-3 and preventing phosphorylation of downstream substrates. This leads to modulation of key signaling pathways involved in disease pathogenesis.
Physicochemical Properties
|
M.Wt |
353.29 |
|
|
Formula |
C17H22Cl2N4 |
|
|
CAS No. |
848591-90-2 |
|
|
Appearance |
Solid |
|
|
Storage |
Solide Powder -20 °C 3years; 4°C 2years |
In Solvent -80°C 6 Months -20°C 1 Months |
|
Solubility |
|
|
|
Chemical Name |
|
|
References
1. Ring DB, et al. Discovery of potent and selective glycogen synthase kinase-3 inhibitors for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013;23(13):3939-43.
2. Murakami M, et al. Inhibition of glycogen synthase kinase-3 by MI-353 induces apoptosis and enhances efficacy of gemcitabine in pancreatic cancer cells. Anticancer Res. 2015;35(7):3579-84.
3. Bilodeau MT, et al. A first-in-human Phase I trial of the selective GSK-3 inhibitor, MI-353. J Clin Pharmacol. 2018;58(5):605-13.
Hot Tags: MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2, China MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2
Send Inquiry
You Might Also Like







